Clinical Trial Update: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study [Phase 1, Phase 2]

View source ↗

Summary

A completed phase 1/2 clinical trial evaluating ABTL0812 in combination with FOLFIRINOX as first-line treatment for metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ABTL0812
• FOLFIRINOX

Snippet

Sponsor: Ability Pharmaceuticals SL | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED